Article
Encorafenib, binimetinib and cetuximab combined therapy for patients with BRAFV600E mutant metastatic colorectal cancer.
Future oncology (London, England) - 1 Feb 2020
Huijberts Sanne Cfa, van Geel Robin Mjm, Bernards Rene, Beijnen Jos H, Steeghs Neeltje
Abstract excerpt
Approximately 10-15% of colorectal cancers (CRCs) harbor an activating BRAF mutation, leading to tumor growth promotion by activation of the mitogen-activated protein kinases pathway. BRAFV600E mutations are prognostic for treatment failure after first-line systemic therapy in the metastatic setting. In contrast to the efficacy of combined BRAF and MEK inhibition in melanoma, BRAFV600E mutant CRC is intrinsically...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.